
|Videos|November 9, 2017
Dr. Larson on Ongoing Trials in Colorectal Cancer
Author(s)Tim G. Larson, MD
Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).
Advertisement
Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).
The BEACON trial is looking at patients with BRAF mutations, which is a small subset of patients with CRC who have a poor prognosis and do not respond to the standard treatments. This trial is offering these patients promising therapies, says Larson.
A different phase III trial is examining the effectiveness of napabucasin (BBI-608), an oral cancer stem cell inhibitor, in the second-line setting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5



































